(Q42999421)

12 November 2017

Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders (English)

1 reference

12 November 2017

Chainuvati S

1

1 reference

12 November 2017

Khalid SK

2

1 reference

12 November 2017

Kancir S

3

1 reference

12 November 2017

Shea M

4

1 reference

12 November 2017

Edwards J

5

1 reference

12 November 2017

Sernyak M

6

1 reference

12 November 2017

Wongcharatrawee S

7

1 reference

12 November 2017

Garcia-Tsao G

8

1 reference

12 November 2017

1 April 2006

1 reference

Journal of Viral Hepatitis

12 November 2017

1 reference

12 November 2017

13

1 reference

12 November 2017

4

1 reference

12 November 2017

235-241

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

12 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

The burden of hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Epidemiology of hepatitis C virus infection in American veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Prevalence of hepatitis C virus seropositivity among hospitalized US veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Elevated prevalence of hepatitis C infection in users of United States veterans medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Management of viral hepatitis: clinical and public health perspectives--a consensus statement. CASL Hepatitis Consensus Group. Canadian Association for Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Psychiatric disorders among veterans with hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Prevalence of hepatitis C among psychiatric patients in the public sector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Limited success of HCV antiviral therapy in United States veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Spectrum of disease in U.S. veteran patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

U.S. veterans' experience with rebetron in a nonstudy environment: success or failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00681.X

10.1111/J.1365-2893.2005.00681.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference